Can-Fite BioPharma Ltd. (CANF) Stock

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, specializes in developing small molecule therapeutic products across multiple therapeutic areas. The company focuses on treatments for cancer, liver inflammatory diseases, and erectile dysfunction. Its robust pipeline includes Piclidenoson, the lead drug candidate that has completed Phase III clinical trials for psoriasis and Phase II trials for COVID-19. Can-Fite is also advancing Namodenoson through Phase III trials for hepatocellular carcinoma and Phase IIb trials for non-alcoholic steatohepatitis. Additionally, CF602 is undergoing pre-clinical trials for the treatment of erectile dysfunction.

Can-Fite BioPharma Ltd. distinguishes itself with innovative research into predictive biomarker blood tests, particularly for the A3AR receptor. These tests are designed to enhance treatment efficacy across its therapeutic portfolio. The company operates under key licensing and collaboration agreements, including partnerships with CMS Medical for Piclidenoson and Namodenoson development, manufacturing, and commercialization. Moreover, collaborations with Univo Pharmaceuticals focus on exploring cannabis components for specific formulations targeting cancer, inflammatory, autoimmune, and metabolic diseases.

Founded in 1994 as Can-Fite Technologies Ltd. and rebranded in January 2001, Can-Fite BioPharma Ltd. has built a reputation for pioneering advancements in biopharmaceuticals. With a commitment to addressing significant medical needs through innovative therapies and biomarker diagnostics, Can-Fite continues to expand its global impact in the healthcare industry.